An Open-label, Single-center, 2-Part, Randomized Study to Assess the Pharmacokinetics of R406 in Healthy Subjects When Fostamatinib 150 mg is Administered Alone in Fed and Fasted State and in Combination With Ranitidine in Fasted State, and to Assess the Relative Bioavailability of Process Variants of Tablets
Phase of Trial: Phase I
Latest Information Update: 27 Dec 2012
At a glance
- Drugs Fostamatinib (Primary) ; Ranitidine
- Indications B-cell lymphoma; Duodenal ulcer; Gastric ulcer; Gastro-oesophageal reflux; Rheumatoid arthritis; Solid tumours
- Focus Pharmacokinetics
- 01 Dec 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 17 Sep 2012 New trial record
- 01 Sep 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.